In yesterday’s Wall Street session, Precigen Inc (NASDAQ:PGEN) shares traded at $1.36, up 1.49% from the previous session.
PGEN stock price is now -2.38% away from the 50-day moving average and -0.34% away from the 200-day moving average. The market capitalization of the company currently stands at $343.29M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
, while ‘Cantor Fitzgerald’ rates the stock as ‘Overweight’
In other news, KIRK RANDAL J, Director bought 96,686 shares of the company’s stock on Dec 28 ’23. The stock was bought for $136,327 at an average price of $1.41. Upon completion of the transaction, the Director now directly owns 1,096,686 shares in the company, valued at $1.49 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 28 ’23, Director KINDLER JEFFREY B sold 96,686 shares of the business’s stock. A total of $136,327 was realized by selling the stock at an average price of $1.41. This leaves the insider owning 238,275 shares of the company worth $0.32 million. A total of 48.83% of the company’s stock is owned by insiders.
During the past 12 months, Precigen Inc has had a low of $0.84 and a high of $1.88. As of last week, the company has a debt-to-equity ratio of 0.07, a current ratio of 1.72, and a quick ratio of 1.72. The fifty day moving average price for PGEN is $1.392 and a two-hundred day moving average price translates $1.3656 for the stock.
The latest earnings results from Precigen Inc (NASDAQ: PGEN) was released for 2024-03-31. According to the Biotechnology Company, earnings per share came in at -0.08, beating analysts’ expectations of -0.1 by 0.02. This compares to -$0.10 EPS in the same period last year. The net profit margin was -1781.72% and return on equity was -68.94% for PGEN. The company reported revenue of $1.06 million for the quarter, compared to $1.85 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -42.46 percent. For the current quarter, analysts expect PGEN to generate $1.28M in revenue.
